Dogwood Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Details)

Stockholders' Equity (Details)								1 Months Ended		9 Months Ended
Stockholders' Equity (Details)	Apr. 21, 2026	Jan. 11, 2026 USD ($) $ / shares shares	Nov. 21, 2025 shares	Sep. 29, 2025 $ / shares shares	Apr. 07, 2025 shares	Mar. 12, 2025 USD ($) $ / shares shares	Oct. 17, 2024	Sep. 30, 2025 USD ($) shares	Oct. 31, 2024 shares	Sep. 30, 2026 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) shares	Jun. 30, 2026 $ / shares shares	Jun. 16, 2026 $ / shares shares	Jun. 15, 2026 shares	Mar. 11, 2026 shares	Jan. 15, 2026 $ / shares shares	Jan. 09, 2026 USD ($)	Dec. 31, 2025 USD ($) $ / shares shares	Nov. 28, 2025 USD ($)	Jun. 30, 2025 shares	Mar. 31, 2025 USD ($) shares	Dec. 31, 2024 shares	Oct. 07, 2024 $ / shares	Dec. 16, 2020 $ / shares shares
Stockholders' Equity
Common and preferred stock authorized (in shares)													200,000,000	45,000,000
Common stock authorized										195,000,000			195,000,000					43,000,000						195,000,000
Common stock, par value (in dollars per share) \| $ / shares										$ 0.0001			$ 0.0001					$ 0.0001						$ 0.0001
Preferred stock authorized								2,000,000	2,000,000		2,000,000	5,000,000	5,000,000								2,000,000
Preferred stock, par value (in dollars per share) \| $ / shares												$ 0.0001	$ 0.0001
Temporary equity, shares authorized										2,104								2,104
Temporary equity, shares outstanding										0								0		2,269.1494	2,213.8044	2,213.8044
Temporary equity, shares issued										0								0
Waiver of cash settlement and related repurchase rights for series A preferred stock								166
Waiver and conversion of preferred stock \| $								$ 5,500,000
Percentage of upfront payment to which holders are entitled									87.75%
Contingent value rights liability \| $										$ 0
Net proceeds from issuance of common stock \| $										$ 11,397,459	$ 4,252,245
Deferred issuance costs \| $																	$ 159,000	$ 158,956
Dividends payable \| $																					$ 1,770,767
Pre-funded Warrants
Stockholders' Equity
Warrants exercise price \| $ / shares										$ 0.0001						$ 0.0001
Warrants to purchase shares																2,047,089
Common Warrants
Stockholders' Equity
Offering price per share \| $ / shares																$ 3.28
Warrants exercise price \| $ / shares										$ 3.28
Warrants exercise period										5 years 6 months
Warrants to purchase shares															4,386,037	4,386,037
Number of warrants issued along with each common stock or warrant		1
PRIDCor Therapeutics, LLC License Agreement
Stockholders' Equity
Revenue remaining performance obligation \| $										$ 0
Preferred Stock Excluding Series A and Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										4,997,254								1,997,254
Series A preferred stock
Stockholders' Equity
Temporary equity, shares authorized									2,270	2,270								2,270
Temporary equity, shares outstanding										0								0
Temporary equity, shares issued										0								0
Preferred stock converted to common stock			10,000
Preferred stock dividend rate percentage										5.00%
Preferred stock dividend payment period					180 days					180 days
PIK dividend, shares					55.345
Series A1 Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										285								285			285
Preferred stock, par value (in dollars per share) \| $ / shares						$ 0.0001
Preferred stock converted to common stock			10,000
Convertible Preferred Stock, Shares Issued upon Conversion						10,000
Preferred stock issued										0								0
Preferred stock outstanding										0								0
Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										285								285
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001								$ 0.0001
Preferred stock issued										0								0
Preferred stock outstanding										0								0
Series A2 Convertible Preferred stock
Stockholders' Equity
Preferred stock authorized								190.0572		190.0572	190.0572							190.0572
Preferred stock converted to common stock			10,000
Preferred stock issued										0								0
Preferred stock outstanding										0								0
Series A-2 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										190.0572								190.0572
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001								$ 0.0001
Preferred stock issued										0								0
Preferred stock outstanding										0								0
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										166								166
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001								$ 0.0001
Preferred stock issued										0								0
Preferred stock outstanding										0								0
Series A Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares				$ 0.0001
Pharmagesic Holdings Inc.
Stockholders' Equity
Preferred stock, par value (in dollars per share) \| $ / shares																							$ 0.0001
Number of contingent value rights issuable for each common share							1
Contingent value rights agreement term							7 years
Percentage of upfront payment to which holders are entitled	87.75%						87.75%
Percentage of upfront payment entitled by entity	12.25%
Contingent value rights liability \| $										$ 0
Percentage ownership of outstanding rights that entitles holder to audit and enforcement							30.00%
Serpin Pharma \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares				$ 0.0001
Total consideration paid				191,017
Serpin Pharma \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development
Stockholders' Equity
Total consideration paid				89.5939
Serpin Registration Rights Agreement \| Common Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid				191,017
Serpin Registration Rights Agreement \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid				89.5939
At the market offering
Stockholders' Equity
Aggregate offering price \| $																			$ 8,558,712
January 2026 Offering
Stockholders' Equity
Offering price per share \| $ / shares		$ 2.85
Net proceeds from issuance of common stock \| $										$ 11,400,000
Offering price \| $ / shares		$ 2.8499
Gross proceeds \| $		$ 12,500,000
January 2026 Offering \| Pre-funded Warrants \| Maximum
Stockholders' Equity
Warrants to purchase shares		2,047,089
January 2026 Offering \| Common Warrants
Stockholders' Equity
Additional Gross Proceeds Receivable From Warrant Exercises \| $		$ 14,400,000
January 2026 Offering \| Common Warrants \| Maximum
Stockholders' Equity
Warrants to purchase shares		4,386,037
Registered Direct Offering
Stockholders' Equity
No of shares issued		2,338,948				578,950
Offering price per share \| $ / shares						$ 8.26
Gross proceeds from issuance of shares \| $						$ 4,780,000
Net proceeds from issuance of common stock \| $						$ 4,250,000